Drug Resistant Epilepsy Pipeline: Insights into Novel Pipeline Therapies, Key Pharma Companies, Growth Prospects and Future Drug Resistant Epilepsy Pipeline Landscape

DelveInsight's, "Drug Resistant Epilepsy Pipeline Insight, 2022," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Drug Resistant Epilepsy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. In the Drug Resistant Epilepsy Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Drug Resistant Epilepsy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key takeaways from the Drug Resistant Epilepsy Pipeline Report
• DelveInsight's Drug Resistant Epilepsy Pipeline analysis depicts the space with 10+ active players working to develop 10+ pipeline therapies.
• The leading Drug Resistant Epilepsy Companies are working such as ES Therapeutics, PTC Therapeutics, Aadi Bioscience, MGC Pharma, UCB, Zogenix, and others.
• Promising Drug Resistant Epilepsy Pipeline therapies such as Padsevonil, NaviFUS System, PLT101, Questionnaires, Vagus Nerve Stimulation (VNS) Therapy, 2.5:1, RWJ-333369, Cathodal Transcranial Direct Current Stimulation (tDCS), and others.
• The Drug Resistant Epilepsy Companies and academics are working to assess challenges and seek opportunities that could influence R&D Drug Resistant Epilepsy. The therapies under development are focused on novel approaches to treat/improve Drug Resistant Epilepsy.

Recent Developmental Activities in the Drug Resistant Epilepsy Pipeline
• Fintepla (fenfluramine) oral solution is a prescription medication approved by the FDA and EMA, and under regulatory review with PMDA (Japan), for the treatment of seizures associated with Dravet syndrome in patients two years of age and older.
• ABI-009 is an mTOR inhibitor complexed with human albumin that has significantly higher tumor accumulation, mTOR target suppression and improved efficacy over other mTOR inhibitors in preclinical models.

Request for Sample to know which pharma company is expected to be at the forefront in the coming years, Drug Resistant Epilepsy Pipeline Outlook Report @ https://www.delveinsight.com/sample-request/drug-resistant-epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Drug Resistant Epilepsy Overview

Drug resistant epilepsy (DRE) is defined as the persistence of seizures despite at least two syndrome-adapted antiseizure drugs (ASD) used at efficacious daily dose. Despite the increasing number of available ASD, about a third of patients with epilepsy still suffer from drug resistance. Several factors are associated with the risk of evolution to DRE in patients with newly diagnosed epilepsy, including epilepsy onset in the infancy, intellectual disability, symptomatic epilepsy and abnormal neurological exam. The prevalence of DRE is 30% (95% CI: 19-42%). Its incidence varies from 15% (95% CI: 11-19%) in children to 34% (95% CI: 6-62%) in adults18 without variation across geographic areas. Among patients with newly diagnosed epilepsy followed for at least two years in the Glasgow cohort, 36% were not seizure free the last year of follow-up.

Drug Resistant Epilepsy Emerging Drugs: Profile
• Fintepla: Zogenix
• ABI-009: Aadi Bioscience

Drug Resistant Epilepsy Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies Drug Resistant Epilepsy. The companies which have their Drug Resistant Epilepsy drug candidates in the most advanced stage, i.e phase II include UCB.

Find out more about Drug Resistant Epilepsy Clinical Trials Analysis @ https://www.delveinsight.com/sample-request/drug-resistant-epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Drug Resistant Epilepsy Report Assessment
• Drug Resistant Epilepsy Pipeline Product Profiles
• Drug Resistant Epilepsy Therapeutic Assessment
• Drug Resistant Epilepsy Pipeline Assessment
• Inactive drugs assessment
• Drug Resistant Epilepsy Unmet Needs

Scope of the Drug Resistant Epilepsy Pipeline Report
• Coverage- Global
• Drug Resistant Epilepsy Companies- ES Therapeutics, PTC Therapeutics, Aadi Bioscience, MGC Pharma, UCB, Zogenix, and others.
• Promising Drug Resistant Epilepsy Pipeline therapies- Padsevonil, NaviFUS System, PLT101, Questionnaires, Vagus Nerve Stimulation (VNS) Therapy, 2.5:1, RWJ-333369, Cathodal Transcranial Direct Current Stimulation (tDCS), and others
• Drug Resistant Epilepsy Key Companies, Key Products, Unmet Needs

Table of Content
1. Introduction
2. Executive Summary
3. Drug-Resistant Epilepsy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Drug Resistant Epilepsy- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Padsevonil: UCB
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. WVE N531: Wave Life Sciences
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. ABI-009: Aadi Bioscience
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Drug Resistant Epilepsy Key Companies
21. Drug Resistant Epilepsy Key Products
22. Drug Resistant Epilepsy- Unmet Needs
23. Drug Resistant Epilepsy- Market Drivers and Barriers
24. Drug Resistant Epilepsy- Future Perspectives and Conclusion
25. Drug Resistant Epilepsy Analyst Views
26. Drug Resistant Epilepsy Key Companies
27. Appendix

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Drug Resistant Epilepsy drugs?
• How many Drug Resistant Epilepsy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Drug Resistant Epilepsy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Drug Resistant Epilepsy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Drug Resistant Epilepsy and their status?
• What are the key designations that have been granted to the emerging drugs?

Download Sample PDF Report for Drug Resistant Epilepsy Clinical trials advancements @ https://www.delveinsight.com/report-store/drug-resistant-epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09193216187
Address: 304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.